Startup Evaro, based in the United Kingdom, which provides clinical services based on artificial intelligence and prescriptions for treating minor medical conditions, announced today that it has raised 1.4 million euros as part of a seed fund. The funding round was led by Cornerstone VC and Exceptional Ventures, with participation from investment arm Catalisi, Syndicate Room, and the University of East Anglia. The funds will be used to develop Evaro’s B2B offering by introducing a ready-made product that allows consumer brands to offer managed prescription services to their customers.
Evaro was founded in 2018 by Dr. Thuria Wenbar, an emergency medicine physician and programmer, and her husband, Dr. Oskar Wendowski, a pharmaceutical researcher. The couple noticed that 25% of emergency consultations and 40% of visits to primary care doctors were for minor health issues. The Evaro team, consisting of doctors, technologists, and experts in the field of digital health, aims to provide scalable, secure, and accessible medical care for residents of the United Kingdom through a self-service model focused on routine health needs.
As it expands its offering in the crowded digital health market, Evaro stands out with its unique B2B approach to “pharmaceutical infrastructure as a service.” It collaborates with consumer brands, offering medications that align with their existing products and customer demographics—for example, dermatological treatments for cosmetic companies. These models allow brands to expand their offerings and increase customer engagement by offering prescription drugs, which traditionally had long wait times within the National Health Service (NHS).
Dr. Wenbar, CEO of Evaro, commented, “The NHS is experiencing a crisis: waiting for a visit to a primary care doctor can now take up to four weeks, which is further exacerbated by funding cuts and staff shortages. The information overload resulting from the widespread availability of AI-based tools increases the risk of self-medication for patients. Our goal is to help people receive faster treatment for their minor health issues in a safe manner, whenever they need it. We aim to achieve this by transforming digital clinics into cost-effective options for major brands.”
Dr. Wendowski added, “We are already helping 350,000 people access healthcare in a simple and secure manner, similar to using online banking. Now we want to scale up our operations. Our B2B strategy focuses on enabling brands in sectors such as cosmetics, sexual health, and travel to enter the digital health field without having to deal with the complexity of technology, regulations, and service delivery, thanks to our ready-to-use service. We hope this will partially relieve first-contact doctors and emergency services from non-urgent visits.”
Evaro utilizes artificial intelligence and machine learning models trained on 13.5 million patient data to enable access to asynchronous consultations conducted by AI and private prescription medications. The company also implements rigorous patient safety procedures that meet regulatory requirements. Within these procedures, online applications requiring treatment undergo asynchronous consultations, and mechanisms for detecting manipulation of responses aim to prevent self-medication. Orders for medications are carefully checked for safe doses and quantities, with the need to notify the patient’s primary care doctor if necessary.
Rodney Appiah, Founder, and CEO at Cornerstone VC, commented, “I was inspired by Thur
The source of the article is from the blog reporterosdelsur.com.mx